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Fused deposition modelling (FDM) 3D printing (3DP) is a revolutionary technology with the 
potential to transform drug product design in both the pre-clinical and clinical arena. The 
objective of this pilot study was to explore the intestinal behaviour of four different polymer-
based devices fabricated using FDM 3DP technology in rats. Small capsular devices of 
8.6mm in length and 2.65mm in diameter were printed from polyvinyl alcohol-polyethylene 
glycol graft-copolymer (PVA-PEG copolymer, Kollicoat IR), hydroxypropylcellulose (HPC, 
Klucel), ethylcellulose (EC, Aqualon N7) and hypromellose acetate succinate (HPMCAS, 
Aquasolve-LG). A smaller sized device, 3.2mm in length and 2.65mm in diameter, was also 
prepared with HPMCAS to evaluate the cut off size of gastric emptying of solid formulations 
in rats.  The devices were radiolabelled with Fluorodeoxyglucose (18F-FDG) and small 
animal positron emission tomography/computed tomography (microPET/CT) was used to 
track the movement and disintegration of the fabricated devices in the rats. The PVA-PEG 
copolymer and HPC devices disintegrated after 60min following oral administration. The EC 
structures did not disintegrate in the gastrointestinal tracts of the rats, whereas the 
HPMCAS-based systems disintegrated after 420min. Interestingly, it was noted that the 
devices which remained intact over the course of the study had not emptied from the 
stomach of the rats. This was also the case with the smaller sized device. In summary, we 
report for the first time, the use of a microPET/CT imaging technique to evaluate the in vivo 
behaviour of 3D printed formulations. The manipulation of the 3D printed device design 
could be used to fabricate dosage forms of varying sizes and geometries with better gastric 
emptying characteristics suitable for rodent administration.  The increased understanding of 
the capabilities of 3DP in dosage form design could, henceforth, accelerate pre-clinical 
testing of new drug candidates in animal models.   
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1. Introduction  
 
Three-dimensional printing (3DP) has the potential to revolutionise the future design and 
manufacture of medicines. With this technology, personalised doses to specific individuals is 
a promising objective (Sanderson 2015). Therefore, 3DP may shift the scope of manufacture 
from mass-produced restricted dose-range unit forms in the pharmaceutical industry to on-
demand production of patient-specific medicines, integrated in pharmacies or hospitals 
(Alomari et al. 2015). Moreover, the ability of 3DP to readily prepare formulations with 
different dose strengths may facilitate pre-clinical studies in animals. This could be used to 
determine a range of safe doses for first-in-man studies and to assess the safety profile of 
new active compounds. 
 
3DP can be used to produce 3D printed solid dosage forms (PrintletsTM) in a repeatable and 
efficient manner, with the capability to combine multiple drugs in one formulation (Goyanes 
et al. 2015c, Khaled et al. 2015b). With the application of intelligent design features (Markl et 
al. 2017), 3DP formulations can exhibit immediate or modified release characteristics, or 
even combinations of these (Goyanes et al. 2015b, Goyanes et al. 2014, Goyanes et al. 
2017, Okwuosa et al. 2017). There are various types of 3DP technologies commercially 
available for pharmaceutical use, namely from stereolithography (Wang et al. 2016), 
selective laser sintering (Fina et al. 2017), and material extrusion, for example (Khaled et al. 
2015a). However, fused-deposition modelling (FDM) remains the most affordable, easy to 
operate and most versatile method of manufacture for unit-dose fabrication (Goyanes et al. 
2015a). In FDM, an extruded filament is passed through a heated nozzle, utilised to soften 
the polymer filament. This allows the formulation to be deposited layer by layer onto the 
build plate of the printer in x-y dimensions to produce the required design. It is possible to 
obtain several drug release profiles from PrintletsTM by altering the parameters of the 3DP 
software, such as the infill, layer thickness (Goyanes et al. 2016) or through excipient 
selection (Goyanes et al. 2017, Melocchi et al. 2015, Melocchi et al. 2016, Okwuosa et al. 
2017).  
 
The use of molecular imaging technologies has optimised the development and evaluation 
of drug delivery systems (Fernandez-Ferreiro et al. 2017, Ding and Wu 2012). These 
technologies involve non-invasive procedures which significantly decrease the number of 
animals used for analysis whilst increasing the number of measurements taken for each 
animal (Cunha et al. 2014, Capozzi et al. 2013). Techniques such as magnetic resonance 
imaging (MRI) (Schiller et al. 2005) and scintigraphy (Tuleu et al. 2007, Weinstein et al. 
2013) have been applied to pharmacokinetic studies for orally-administered dosage forms. 
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Morphological techniques such as computed tomography (CT), for example, have also been 
used for the tracing of capsules along the gastrointestinal (GI) tract (Saphier et al. 2010). 
Unlike other medical imaging techniques, CT enables the direct imaging and differentiation 
of soft tissue structures. In addition, due to short scanning times of approximately 500 
milliseconds to a few seconds, CT can be used for all anatomic regions, including those 
susceptible to motion and breathing. Positron emission tomography (PET) is a further 
example of a functional imaging technique used for pharmacokinetic studies of oral dosage 
forms (Shingaki et al. 2012). PET allows for a three dimensional mapping of positron 
emitting radiopharmaceuticals to detect blood flow, glucose metabolism and receptor 
densities in biological tissues (Lameka, Farwell and Ichise 2016). The use of integrated 
information from PET and CT technologies enable radiopharmaceutical release data to be 
obtained in combination with the anatomical position of the formulation at different times, 
and thus, creates a powerful imaging tool (Anand, Singh and Dash 2009).   
 
As rodents are often used in the pre-clinical arena (Hatton et al. 2015), the aim of this pilot 
study was to investigate the in vivo behaviour of four different FDM 3D printed structures in 
rats. Printed devices with different release characteristics, dependent on polymer 
composition, were fabricated. This included a polyvinyl alcohol/polyethylene glycol graft 
copolymer (PVA-PEG graft-copolymer, immediate release), hydroxypropylcellulose (HPC, 
non-ionic water-soluble), ethylcellulose (EC, non-soluble sustained release) and 
hydroxypropyl methylcellulose acetate succinate LG (HPMCAS, pH dependent). The 
capsular devices were prepared with different lengths (2.65mm diameter x 8.6mm length 
and 2.65 mm diameter x 3.2 mm length) to evaluate the cut off size of gastric emptying of 
solid dosage forms in rats. The selected shell was designed to be 0.5mm thick in order to 
develop formulations that were more resistant to the contractions of the GI tract. In addition, 
the shell would provide a more reliable drug release profile of the different regions of the GI 
tract. These 3DP devices were characterised by microPET/CT in order to evaluate their in 
vivo performance in rats. To the authors’ knowledge, there are currently no previous 
examples of in vivo studies regarding FDM 3D printed formulations using rodent models. 
Therefore, the work reported is the first study of its kind to evaluate the feasibility of using 
fused microPET/CT technologies as a method of investigating the passage and 





2. Materials and methods 
 
Materials 
Fluorodeoxyglucose (18F-FDG) TRACERlab MX synthesizer (GE Healthcare®) was used as 
a tracer. 
 
Four types of polymers were investigated as the main excipient: polyvinyl 
alcohol/polyethylene glycol graft copolymer – PVA/PEG (Kollicoat® IR, an immediate release 
polymer) was obtained from BASF, Germany; hydroxypropylcellulose - HPC (Klucel® EF, a 
non-ionic water soluble polymer), ethylcellulose – EC (Aqualon® N7, a non-soluble polymer) 
and hydroxypropylmethylcellulose acetate succinate - HPMCAS LG (Aquasolve®-LG, a pH 
dependent polymer with a pH threshold of 5.5 (Rowe, Sheskey and Quinn 2009)) were 
obtained from Ashland, UK. D-Mannitol (Sigma-Aldrich, UK) and methylparaben NF grade 
(Amresco, USA) were used as a plasticizer. Magnesium stearate and Talc (Sigma-Aldrich, 
UK) were used as lubricants. 
AquaCem® a light-yellow, translucent glass-ionomer luting material consisting of a blend of 





Preparation of filaments by hot melt extrusion (HME) 
Filaments of different polymers were prepared via hot melt extrusion. The appropriate 
excipients were weighed and mixed using a pestle and mortar to produce a uniform powder 
of 40g in weight (Table 1). The mixture was then extruded using a single-screw filament 
extruder (Noztec Pro hot melt extruder, Noztec, UK) in order to obtain the filament (extrusion 
temperature 105-145°C, Table 1, nozzle diameter 1.75mm, screw speed 15rpm). The 





3D Printing of the devices  
Devices were fabricated from the extruded filaments using a standard MakerBot Replicator 
2X Desktop 3D Printer (MakerBot Inc., USA). The templates used to print the devices were 
designed with 123D Design Software (Autodesk Inc., USA) and exported as a 
stereolithography file (.stl) into the 3D printer software (MakerWare v. 2.4.1, MakerBot Inc., 
USA).  
 
The device design selected (8.6mm length x 2.65mm diameter, shell thickness of 0.5mm, 
Figure 1) is an adaptation from a size 9 capsule used for dosing of small rodents. Smaller 
capsular devices with a length of 3.2 mm x 2.65mm diameter were also prepared. 
 
 
Figure 1. 3D representation of the capsular device (8.6mm length x 2.65mm diameter - 
0.5mm shell thickness), cross section (front) and complete (back) 
 
The printer settings were as follows: the infill percentage of the shell was 100%, a high 
resolution with the raft option was activated and, the speed whilst extruding was 3mm/s, the 
speed while traveling was 25mm/s, the z-axis travel speed was at 23mm/s, the number of 



















Kollicoat IR 45 -  - 20 20 10 145 
Klucel EF - 73.75  - - 21.25  130 
Aqualon N7   75  20   120 
Aquasolve-LG - -  70 15 - 10 105 
 *5% Magnesium Stearate was used in all the formulations as a lubricant 
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shells was 2 and the layer height set at 0.10mm. Printing temperatures were modified 
depending on the type of filaments used to print the device (Table 2).  
 






Kollicoat IR 155 40 
Klucel EF 160 0 
Aqualon N7 160 0 
Aquasolve LG 175 0 
 
 
X-ray Micro Computed Tomography (Micro-CT) 
A high-resolution X-ray micro computed tomography scanner (SkyScan1172, Bruker-
microCT, Belgium) was used to 3D visualize the structure of the 3D printed devices. 
Samples were scanned without the use of a filter at a resolution of 2000x1048 pixels. Image 
reconstruction was performed using NRecon software (version 1.7.0.4, Bruker-microCT). 
Beam hardening, ring artefacts and post alignments were adjusted to achieve the best 
possible images. 3D model rendering and viewing were performed using the associate 
program CT-Volume (CTVol version 2.3.2.0) software. The collected data was analysed 
using the software CTVox (CTVox version 3.2).  
 
Device morphology characterisation 
Pictures of the devices were taken with a Nikon CoolpixS6150 with the macro option 
activated. 
 
In vivo microPET/CT studies 
Once printed, the devices were cut 1mm from the end using a scalpel and filled with 
approximately 5µL of 18F-FDG with an activity of 3MBq using a HPLC syringe. The dental 
cement (AquaCem®) was used to close the devices. One spatula of adhesive powder 
(approx. 100mg) was mixed with two drops of water (approx. 30mg) to prepare the adhesive 
paste. The paste was applied using a small spatula onto the removed portions of the devices 
that were reattached to the larger section in less than 2min after mixing of the adhesive. 




This study was carried out on male Sprague-Dawley rats with an average weight of 300g 
supplied by the animal facility at the University of Santiago Compostela (USC). During the 
experiment, the animals were kept in individual cages with free access to food and water in 
a room under controlled temperature (22±1ºC) and humidity (60±5%) conditions and with 
day-night cycles regulated by artificial light (12/12h). For the administration of the 3D printed 
devices, the animals were placed in a gas chamber containing 2% isoflurane in oxygen to 
induce anaesthesia. The radiolabelled devices were introduced directly into the stomach of 
the rats using a Torpac® dosing syringe for rodents. Four rats were used for testing each 
type of device. 
 
MicroPET/CT acquisition 
PET/CT images were acquired using an Albira microPET/CT Preclinical Imaging System 
(Bruker Biospin, Woodbridge, Connecticut, United States). The PET subsystem comprises 
three rings of eight compact modules based on monolithic crystals coupled to multi-anode 
photomultiplier tubes (MAPMTs), forming an octagon with an axial FOV of 40mm per ring 
and a transaxial FOV of 80mm in diameter. The computed tomography (CT) system 
comprises a microfocus x-ray tube and a CsI scintillator 2D pixelated flat panel detector. 
Immediately after the administration of the device, the animals were positioned onto the bed 
of the scanner to allow dynamic PET acquisitions at predetermined time intervals. Rats 
remained conscious for most of the experiment and only were anesthetized during PET/CT 
acquisition. No contrast or prokinetic agents were administered to the rats.  
 
PET/CT image analysis 
Firstly, device disintegration was assessed by visual inspection of the spread of the tracer. 
Furthermore, CT images were obtained for evaluation of the gastric retention and fused 
PET/CT images were used to track the devices along the gastrointestinal tract. Quantitative 
analysis was carried out by using Regions of Interest (ROIs) manually delineated on the 
position of the device. This was obtained from the first PET image frame and overlapped on 
subsequent image frames. The average activity of the radiotracer in the device was 
gathered over time. The effect of the radioactive decay was calculated (110min halftime for 
18F-FDG) and removed from the measurements. Results are presented as the % of 
radioactivity remaining in the device over time. 
 
Results and Discussion 
 
Four types of 3D printed devices were fabricated with filaments obtained by hot melt 
extrusion (HME) using four base polymers, namely an immediate-release polymer (Kollicoat 
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IR, PVA-PEG copolymer), a non-ionic water-soluble polymer (Klucel EF, HPC), an insoluble 
polymer (Aqualon N7, EC) and a pH dependent polymer with a pH threshold of 5.5 
(Aquasolve-LG, HPMC-AS LG) (Figure 2).  
 
 
Figure 2. From left to right pictures of 3D printed devices of Kollicoat IR, Klucel EF, Aqualon 
N7 and Aquasolve-LG (units are cm). 
 
These polymers were selected based on their different dissolution characteristics. Alongside 
the chosen polymer, the filaments further incorporated a plasticiser (methylparaben or 
mannitol) and a lubricant (talc or magnesium stearate) (Table 1). The inclusion of 
plasticisers and lubricants in the correct ratios was crucial to obtain filaments that would 
have the required properties for printing capsular devices of such small a size. In a previous 
study (Melocchi et al. 2016), disks fabricated by FDM printing with similar types of polymers 
were used as a simple model to evaluate the performance of printed barriers when in 
contact with aqueous fluids using an in vitro test cell assembly. It was found that the 
optimisation of the formulation with the use of plasticisers and lubricants was required to 
enhance the printability of these filaments, and thus, refined the printing characteristics of 
smaller objects. The optimal printing temperature and settings were determined and are 
outlined in the printing results (Table 2).  
 
MicroCT images revealed that all fabricated devices were not compromised and showed no 
visible holes in the surface of the shells (Figure 3). The Aquasolve-LG devices appeared to 
be less uniform in its deposition, however, exhibiting a more deformed shape. Visual 
analysis of the Aquasolve-LG device showed a slight reduction in its volume when compared 
with the other FDM printed devices.  
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Figure 3. Micro-CT images of 3D printed devices made of: A) Kollicoat IR, B) Klucel EF, C) 
Aqualon N7 and D) Aquasolve-LG 
 
In order to evaluate their release properties, the 3D printed devices were cut and 
reassembled following the introduction of the 18F-FDG marker. It might have been possible 
to load the tracer into the capsular devices using a dual FDM 3D printer with two filaments; 
one for the external shell and other for the core (Markl et al. 2017, Okwuosa et al. 2017, 
Goyanes et al. 2015c). However, in our study, we followed a manual approach for two 
reasons; firstly, to avoid the contamination of the printers with the radiotracer and; secondly, 
due to the short half-life of 18F-FDG. This was necessary as the printing process and the 
PET study were performed at different institutions. It has been reported that it is possible to 
print the body and cap of a capsule separately and then join them together after filling 







approach was not feasible with the current study due to the small size of the devices needed 
for administration to rodents. 
 
The devices were placed into the stomach of the rats and the behaviour of the devices within 
the GI tract were evaluated by PET/CT imaging. The results indicated that the disintegration 
of the devices were identified at different times following oral administration in rats, although 
this was dependent on the type of device (Figure 4). 
 
 
Figure 4. Coronal views of PET images after oral administration of radiolabelled Kollicoat IR, 
Klucel EF, Aqualon N7 and Aquasolve-LG devices. The black hue indicates high levels of 
radioactivity. 
 
The combination of PET and CT technologies allowed the location of the device in the GI 
tract to be visualised. The in vivo disintegration of the Kollicoat and Klucel devices 
demonstrated similar release behaviours, occurring in the stomach between 60min and 
120min after administration (Figure 5). Kollicoat IR is a pharmaceutical excipient that was 
specifically designed to manufacture instant release tablets (Janssens et al. 2007). The 
thickness of the device (approximately 0.5mm), however, is much thicker than the regular 





Aqualon-based devices remained unchanged and did not exhibit any signs of disintegration 
after 11 hours. Although the polymer is not soluble, Aqualon is normally incorporated to 
manufacture sustained release tablets where the drug dissolution rate is controlled by drug 
diffusion through the coating of the tablet. In this case, the diffusion of tracer was not 
observed through the wall of the capsular device, indicating that the wall was too thick. It has 
been established that drug release is dependent on barrier thickness (Melocchi et al. 2016, 
Okwuosa et al. 2017) and therefore, the preparation of devices with thinner walls could 
represent a strategy to achieve the release of the tracer from the devices over time. Finally, 
the disintegration of Aquasolve was clearly delayed, showing a disintegration time between 
420 to 540min.  
 
Figure 5. Dynamic study of disintegration behaviour of the four capsular devices (n=4).  
 
Fused PET/CT images taken after the administration of Kollicoat, Klucel, Aqualon and 
Aquasolve devices showed that all the devices were retained in the stomach without passing 
to the small intestine prior to disintegration. As an example, Figure 6 shows the fused 



























Figure 6. Fused image PET/CT. a) Prior to the administration of the Klucel device b) 10min 
c) 120min and d) 360min post-administration. 
 
The long disintegration lag time of Aquasolve (more than 420 minutes) could be explained 
by the fact that the devices did not empty the stomach. Aquasolve-LG is known to dissolve 
at pH 5.5, however, the gastric pH of the rat is between 3 and 5 (Hatton et al. 2015, 
McConnell, Basit and Murdan 2008), and thus, provides a rationale for its retarded 
dissolution. A possible explanation for the lack of gastric emptying in rats might be related to 
the size of the dosage form. The study was repeated with smaller Aquasolve devices with a 
length of 3.2mm (compared with the standard 8.6mm length of x 2.65mm diameter). After 
administration of these smaller devices to the rats, however, the results surprisingly showed 
that none of these formulations emptied from the stomach either.  
 
The gastric emptying or retention of orally-administered dosage forms in rodent models are 
currently poorly understood and are subject to varying parameters such as: gastric mobility 
(Dalziel et al. 2017), size of dosage form (Dalziel et al. 2016), the effect of anaesthesia 
(Yamashita et al. 2011) and potentially pre- or post-prandial states (Mori 1989), to name a 
few. A study, for example, demonstrated that enteric-coated gelatine size 9 capsules were 
able to empty from the stomach of a rat between 2 to 8h after administration (Albrecht et al. 
2006). With the use of single-PET/CT x-ray technology, another study demonstrated that 
enteric-coated capsules emptied from the stomach and liberated the nanoparticle contents in 
the proximal region of the small intestine (Sonaje et al. 2010). In other studies, enteric 
coated capsules were reported to be released in the lower GI tract (Hatch et al. 2006, Shah, 
Nutan and Khan 2004, Oveisi et al. 2004). Despite a number of studies suggesting that size 
9 coated capsules do empty from the stomach, contention still remains to whether these 
devices are the optimum dimensions or geometries. A study showed that only capsules up 
Initial 10 min 120 min 360 min 
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to 3.5mm in diameter and 4.8mm in length are able to do so (Saphier et al. 2010). In the 
same study, capsules emptied more rapidly from fed stomachs when compared with fasted 
rats. This finding was unexpected as food is generally considered to delay gastric emptying 
(Varum, Hatton and Basit 2013). Therefore, a better understanding of gastric emptying and 
retention can be explored through 3DP due to its capabilities of fabricating varying shapes 
and sizes, which can also manipulate drug release characteristics (Goyanes et al. 2015c). 
 
3. Conclusions  
 
This is the first study to demonstrate the viability of FDM 3DP as a meaningful and feasible 
method of manufacturing of small capsular devices, as evaluated in vivo studies with the 
utilisation of microPET/CT imaging. The devices were successfully 3D printed using four 
different polymer filaments: Kollicoat IR (immediate release), Klucel EF (water soluble), 
Aqualon N7 (insoluble polymer) and Aquasolve-LG (pH dependent). MicroPET/CT imaging 
offered valuable in vivo data of the behaviour of 3DP devices, using the rat as a model 
animal. Kollicoat IR and Klucel EF devices disintegrated within 1 to 2h, whilst Aquasolve-LG 
devices took longer than 7h to disintegrate. Aqualon N7 devices did not disintegrate or 
release the tracer and gastric emptying was not observed for any of the devices. In addition, 
this study contributed to the identified inconsistencies regarding the lack of gastric emptying 
of modified release in in vivo studies. Therefore, this pilot study confirmed that 3DP is 
capable of printing solid dosage forms, however, further work should be employed to 
fabricate different geometries and smaller devices to successfully empty from the stomach of 
rats. In summary, the work has highlighted the potential of FDM 3DP in the design of 
formulations suitable for pre-clinical testing of drugs, and thus, offer advantages towards 





Albrecht, K., M. Greindl, C. Kremser, C. Wolf, P. Debbage & A. Bernkop-Schnürch (2006) 
Comparative in vivo mucoadhesion studies of thiomer formulations using magnetic 
resonance imaging and fluorescence detection. Journal of Controlled Release, 115, 
78-84. 
Alomari, M., F. H. Mohamed, A. W. Basit & S. Gaisford (2015) Personalised dosing: Printing 
a dose of one's own medicine. Int J Pharm, 494, 568-77. 
Anand, S. S., H. Singh & A. K. Dash (2009) Clinical Applications of PET and PET-CT. 
Medical Journal, Armed Forces India, 65, 353-358. 
Capozzi, M. E., A. Y. Gordon, J. S. Penn & A. Jayagopal (2013) Molecular imaging of retinal 
disease. J Ocul Pharmacol Ther, 29, 275-86. 
Cunha, L., K. Szigeti, D. Mathe & L. F. Metello (2014) The role of molecular imaging in 
modern drug development. Drug Discov Today, 19, 936-48. 
Dalziel, J. E., K. Fraser, W. Young, C. M. McKenzie, S. A. Bassett & N. C. Roy (2017) 
Gastroparesis and lipid metabolism-associated dysbiosis in Wistar-Kyoto rats. Am J 
Physiol Gastrointest Liver Physiol, 313, G62-G72. 
Dalziel, J. E., W. Young, P. Bercik, N. J. Spencer, L. J. Ryan, K. E. Dunstan, C. M. Lloyd-
West, P. K. Gopal, N. W. Haggarty & N. C. Roy (2016) Tracking gastrointestinal 
transit of solids in aged rats as pharmacological models of chronic dysmotility. 
Neurogastroenterol Motil, 28, 1241-51. 
Ding, H. & F. Wu (2012) Image Guided Biodistribution and Pharmacokinetic Studies of 
Theranostics. Theranostics, 2, 1040-1053. 
Fernandez-Ferreiro, A., J. Silva-Rodriguez, F. J. Otero-Espinar, M. Gonzalez-Barcia, M. J. 
Lamas, A. Ruibal, A. Luaces-Rodriguez, A. Vieites-Prado, T. Sobrino, M. Herranz, L. 
Garcia-Varela, J. Blanco-Mendez, M. Gil-Martinez, M. Pardo, A. Moscoso, S. Medin-
Aguerre, J. Pardo-Montero & P. Aguiar (2017) Positron Emission Tomography for the 
Development and Characterization of Corneal Permanence of Ophthalmic 
Pharmaceutical Formulations. Invest Ophthalmol Vis Sci, 58, 772-780. 
Fina, F., A. Goyanes, S. Gaisford & A. W. Basit (2017) Selective laser sintering (SLS) 3D 
printing of medicines. International Journal of Pharmaceutics, 529, 285-293. 
Goyanes, A., A. B. Buanz, A. W. Basit & S. Gaisford (2014) Fused-filament 3D printing 
(3DP) for fabrication of tablets. International Journal of Pharmaceutics, 476, 88-92. 
Goyanes, A., A. B. Buanz, G. B. Hatton, S. Gaisford & A. W. Basit (2015a) 3D printing of 
modified-release aminosalicylate (4-ASA and 5-ASA) tablets. Eur J Pharm Biopharm, 
89, 157-162. 
Goyanes, A., H. Chang, D. Sedough, G. B. Hatton, J. Wang, A. Buanz, S. Gaisford & A. 
Basit (2015b) Fabrication of controlled-release budesonide tablets via desktop (FDM) 
3D printing International Journal of Pharmaceutics, 496, 414-420. 
Goyanes, A., F. Fina, A. Martorana, D. Sedough, S. Gaisford & A. W. Basit (2017) 
Development of modified release 3D printed tablets (printlets) with pharmaceutical 
16 
 
excipients using additive manufacturing. International Journal of Pharmaceutics, 527, 
21-30. 
Goyanes, A., M. Kobayashi, R. Martinez-Pacheco, S. Gaisford & A. W. Basit (2016) Fused-
filament 3D printing of drug products: Microstructure analysis and drug release 
characteristics of PVA-based caplets. Int J Pharm, 514, 290-295. 
Goyanes, A., J. Wang, A. Buanz, R. Martinez-Pacheco, R. Telford, S. Gaisford & A. W. Basit 
(2015c) 3D Printing of Medicines: Engineering Novel Oral Devices with Unique 
Design and Drug Release Characteristics. Mol Pharm, 12, 4077-84. 
Hatch, M., J. Cornelius, M. Allison, H. Sidhu, A. Peck & R. W. Freel (2006) Oxalobacter sp. 
reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney 
International, 69, 691-698. 
Hatton, G. B., V. Yadav, A. W. Basit & H. A. Merchant (2015) Animal Farm: Considerations 
in Animal Gastrointestinal Physiology and Relevance to Drug Delivery in Humans. J 
Pharm Sci, 104, 2747-76. 
Janssens, S., H. N. de Armas, J. P. Remon & G. Van den Mooter (2007) The use of a new 
hydrophilic polymer, Kollicoat IR®, in the formulation of solid dispersions of 
Itraconazole. European Journal of Pharmaceutical Sciences, 30, 288-294. 
Khaled, S. A., J. C. Burley, M. R. Alexander, J. Yang & C. J. Roberts (2015a) 3D printing of 
five-in-one dose combination polypill with defined immediate and sustained release 
profiles. Journal of Controlled Release, 217, 308-14. 
Khaled, S. A., J. C. Burley, M. R. Alexander, J. Yang & C. J. Roberts (2015b) 3D printing of 
tablets containing multiple drugs with defined release profiles. International Journal of 
Pharmaceutics, 494, 643-50. 
Lameka, K., M. D. Farwell & M. Ichise. 2016. Chapter 11 - Positron Emission Tomography. 
In Handbook of Clinical Neurology, eds. J. C. Masdeu & R. G. González, 209-227. 
Elsevier. 
Liu, F., R. Lizio, C. Meier, H. U. Petereit, P. Blakey & A. W. Basit (2009) A novel concept in 
enteric coating: a double-coating system providing rapid drug release in the proximal 
small intestine. J Control Release, 133, 119-24. 
Markl, D., J. A. Zeitler, C. Rasch, M. H. Michaelsen, A. Mullertz, J. Rantanen, T. Rades & J. 
Botker (2017) Analysis of 3D Prints by X-ray Computed Microtomography and 
Terahertz Pulsed Imaging. Pharmaceutical Research, 34, 1037-1052. 
McConnell, E. L., A. W. Basit & S. Murdan (2008) Measurements of rat and mouse 
gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo 
experiments. J Pharm Pharmacol, 60, 63-70. 
Melocchi, A., F. Parietti, G. Loreti, A. Maroni, A. Gazzaniga & L. Zema (2015) 3D printing by 
fused deposition modeling (FDM) of a swellable/erodible capsular device for oral 
pulsatile release of drugs. Journal of Drug Delivery Science and Technology, 30, 
360-367. 
Melocchi, A., F. Parietti, A. Maroni, A. Foppoli, A. Gazzaniga & L. Zema (2016) Hot-melt 
extruded filaments based on pharmaceutical grade polymers for 3D printing by fused 
deposition modeling. International Journal of Pharmaceutics, 509, 255-263. 
17 
 
Mori, M., Shirai, Y., Uezono, Y., Takahashi, T., Nakamura, Y., Makita, H., Nakanishi, Y. and 
Imasato, Y. (1989) Influence of Specific Gravity and Food on Movement of Granules 
in the Gastrointestinal Tract of Rats. Chemical and Pharmaceuitcal Bulletin, 37, 738-
741. 
Okwuosa, T. C., B. C. Pereira, B. Arafat, M. Cieszynska, A. Isreb & M. A. Alhnan (2017) 
Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for 
Patient-Centred Therapy. Pharmaceutical Research, 34, 427-437. 
Oveisi, F., S. Gaetani, K. T.-P. Eng & D. Piomelli (2004) Oleoylethanolamide inhibits food 
intake in free-feeding rats after oral administration. Pharmacological Research, 49, 
461-466. 
Rowe, R. C., P. J. Sheskey & M. E. Quinn. 2009. Handbook of pharmaceutical excipients. 
London: Pharmaceutical Press and American Pharmacists Association. 
Sanderson, K. (2015) 3D printing: the future of manufacturing medicine? The 
Pharmaceutical Journal, 294, No 7865. 
Saphier, S., A. Rosner, R. Brandeis & Y. Karton (2010) Gastro intestinal tracking and gastric 
emptying of solid dosage forms in rats using X-ray imaging. Int J Pharm, 388, 190-5. 
Schiller, C., C. P. Frohlich, T. Giessmann, W. Siegmund, H. Monnikes, N. Hosten & W. 
Weitschies (2005) Intestinal fluid volumes and transit of dosage forms as assessed 
by magnetic resonance imaging. Aliment. Pharmacol. Ther., 22, 971-979. 
Shah, R. B., M. Nutan & M. A. Khan (2004) An Enteric Dual‐Controlled Gastrointestinal 
Therapeutic System of Salmon Calcitonin‐I: Preparation, Characterization, and 
Preclinical Bioavailability in Rats. Clinical Research and Regulatory Affairs, 21, 81-
96. 
Shingaki, T., T. Takashima, Y. Wada, M. Tanaka, M. Kataoka, A. Ishii, Y. Shigihara, Y. 
Sugiyama, S. Yamashita & Y. Watanabe (2012) Imaging of gastrointestinal 
absorption and biodistribution of an orally administered probe using positron 
emission tomography in humans. Clinical Pharmacology and Therapeutics, 91, 653-
659. 
Sonaje, K., Y.-J. Chen, H.-L. Chen, S.-P. Wey, J.-H. Juang, H.-N. Nguyen, C.-W. Hsu, K.-J. 
Lin & H.-W. Sung (2010) Enteric-coated capsules filled with freeze-dried 
chitosan/poly(γ-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials, 31, 
3384-3394. 
Tuleu, C., M. K. Khela, D. F. Evans, B. E. Jones, S. Nagata & A. W. Basit (2007) A 
scintigraphic investigation of the disintegration behaviour of capsules in fasting 
subjects: a comparison of hypromellose capsules containing carrageenan as a 
gelling agent and standard gelatin capsules. European Journal of Pharmaceutical 
Sciences: Official Journal of the European Federation for Pharmaceutical Sciences, 
30, 251-255. 
Varum, F. J., G. B. Hatton & A. W. Basit (2013) Food, physiology and drug delivery. 
International Journal of Pharmaceutics, 457, 446-60. 
Wang, J., A. Goyanes, S. Gaisford & A. W. Basit (2016) Stereolithographic (SLA) 3D printing 




Weinstein, D. H., S. deRijke, C. C. Chow, L. Foruraghi, X. Zhao, E. C. Wright, M. Whatley, 
R. Maass-Moreno, C. C. Chen & S. A. Wank (2013) A new method for determining 
gastric acid output using a wireless pH-sensing capsule. Alimentary Pharmacology & 
Therapeutics, 37, 1198-1209. 
Yamashita, S., T. Takashima, M. Kataoka, H. Oh, S. Sakuma, M. Takahashi, N. Suzuki, E. 
Hayashinaka, Y. Wada, Y. Cui & Y. Watanabe (2011) PET imaging of the 
gastrointestinal absorption of orally administered drugs in conscious and 
anesthetized rats. Journal of Nuclear Medicine: Official Publication, Society of 
Nuclear Medicine, 52, 249-256. 
 
